Glioblastoma

44 trials 19 recruiting MedDRA PT
44 Registered trials
19 Recruiting
38 Unique sponsors
28 Unique IMPs
19 Commercial trials
Drug classes (ATC)
— ATC code not specified 27
L Oncology (ATC L) 12
V Various (ATC V) 2
J Anti-infectives (ATC J) 1
C Cardiology (ATC C) 1
M Musculoskeletal (ATC M) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 18 substances
Checkpoint inhibitor (PD-1) 2 substances
Alkylating agent 1 substance
Platinum compound 1 substance
CDK inhibitor 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Antimetabolite 1 substance
Azole antifungal 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
ARB 1 substance
Phase III: 5 Phase II/III: 3 Phase II: 9 Phase I/II: 4 Phase I: 4 Phase I (Other): 13 Phase I (First in Human): 6

Filter these 44 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 44 trials

Phase III

5 trials
  • Carthera Commercial
    CARBOPLATIN; PERFLUTREN
    2023-505829-14-00 9 countries 2023 n=351
    Halted
  • Novocure GmbH Commercial
    PEMBROLIZUMAB
    2024-513550-30-00 6 countries 2025 n=280
    Recruiting
  • Telix Pharmaceuticals (Innovations) Pty Limited Commercial
    4-IODOPHENYLALANINE I-131
    2025-521785-10-00 3 countries 2026 n=30 Orphan
    Recruiting
  • Centre Oscar Lambret Academic
    IMP not specified
    2022-500451-23-00 2 countries 2019 n=460
    Ended
  • European Organisation For Research And Treatment Of Cancer Academic
    IMP not specified
    2023-505267-36-00 10 countries 2024 n=371
    Recruiting

Phase II/III

3 trials
  • Global Coalition For Adaptive Research Inc. Commercial
    7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE; PEGARGIMINASE; TRORILUZOLE
    2024-511452-40-00 2 countries 2025 n=120
    Ended
  • Laminar Pharmaceuticals S.A. Commercial
    IDROXIOLEIC ACID; TEMOZOLOMIDE
    2024-511542-39-00 3 countries 2019 n=106 Orphan
    Ended
  • Oslo University Hospital HF Academic
    TEMOZOLOMIDE
    2024-518663-35-00 1 country 2018 n=60
    Recruiting

Phase II

9 trials
  • Azienda Ospedaliera Universitaria Meyer IRCCS Academic
    IMP not specified
    2024-519135-41-00 1 country 2022 n=20
    Ended
  • Heinrich-Heine-Universitaet Duesseldorf Academic
    AUTOLOGOUS MATURE DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE
    2024-514820-18-00 1 country 2018 n=136
    Ended
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. Academic
    AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS; TEMOZOLOMIDE
    2024-512493-98-00 1 country 2021 n=28
    Recruiting
  • Oslo University Hospital HF Academic
    LOSARTAN POTASSIUM
    2023-507575-22-00 1 country 2019 n=153
    Ended
  • Pauls Stradins Clinical University Hospital Academic
    ZOLEDRONIC ACID MONOHYDRATE
    2024-519446-67-00 1 country 2025 n=80
    Recruiting
  • Rheinische Friedrich-Wilhelms-Universitaet Bonn Academic
    MECLOFENAMATE SODIUM
    2024-511264-89-00 1 country 2022 n=72
    Recruiting
  • Universitaet Muenster Academic
    AMINOLEVULINIC ACID HYDROCHLORIDE
    2023-509238-20-00 1 country 2025 n=14
    Ended
  • Universitaetsklinikum Heidelberg AöR Academic
    PERAMPANEL
    2023-503938-52-00 1 country 2024 n=66
    Recruiting
  • Universitaetsklinikum Tuebingen AöR Academic
    BEVACIZUMAB
    2024-514865-20-00 1 country 2024 n=146
    Recruiting

Phase I/II

4 trials
  • Debiopharm International S.A. Commercial
    3-(2,6-DICHLOROPHENYL)-2,3-DIHYDRO-1-METHYL-7-[[3-METHYL-4-(1-METHYL-4-PIPERIDINYL)PHENYL]AMINO]-PYRIMIDO[4,5-D]PYRIMIDIN-4(1H)-ONE; TEMOZOLOMIDE
    2022-502156-31-00 1 country 2023 n=55
    Recruiting
  • Novartis Pharma AG Commercial
    RIBOCICLIB
    2024-512095-35-00 7 countries 2022 n=49
    Ended
  • TME Pharma AG Commercial
    BEVACIZUMAB; OLAPTESED PEGOL; PEMBROLIZUMAB; TEMOZOLOMIDE
    2024-510964-21-00 1 country 2019 n=136 Orphan
    Recruiting
  • Universitaet Muenster Academic
    AMINOLEVULINIC ACID HYDROCHLORIDE
    2024-517651-12-00 1 country 2022 n=33
    Recruiting

Phase I

4 trials
  • Double Bond Pharmaceutical AB Commercial
    IMP not specified
    2024-515128-35-00 2 countries n=27
    Pending
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2024-513687-26-00 2 countries 2025 n=26
    Recruiting
  • Universitaetsklinikum Muenster AöR Academic
    IMP not specified
    2024-513638-39-00 1 country 2022 n=15
    Ended
  • Universitair Medisch Centrum Groningen Academic
    IMP not specified
    2024-513392-40-01 1 country 2023 n=21
    Recruiting

Phase I (Other)

13 trials
  • Boehringer Ingelheim International GmbH Commercial
    IMP not specified
    2023-506409-20-00 2 countries 2023 n=14
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2024-511171-15-00 6 countries 2020 n=216
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502134-10-00 5 countries 2024 n=40
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-506719-17-00 3 countries 2022 n=34
    Ended
  • Oncopeptides AB Commercial
    IMP not specified
    2026-525543-32-00 1 country n=10
    Pending
  • Centre Francois Baclesse Academic
    IMP not specified
    2024-514144-85-02 1 country n=91
    Pending
  • Grupo Espanol De Investigacion En Neurooncologia Academic
    IMP not specified
    2024-515546-16-00 1 country 2024 n=33
    Ended
  • Istituto Oncologico Veneto Academic
    IMP not specified
    2024-514424-16-00 1 country 2022 n=36
    Ended
  • Oslo University Hospital HF Academic
    GEMCITABINE
    2023-510214-11-00 1 country 2023 n=15
    Recruiting
  • Otto Von Guericke Universitaet Magdeburg Academic
    ITRACONAZOLE
    2024-519239-40-01 1 country 2025 n=15
    Recruiting
  • Region Midtjylland Academic
    IMP not specified
    2025-522605-37-00 1 country 2026 n=36
    Recruiting
  • UZ Brussel Academic
    CD1C+/CD141+ MYELOID DENDRITIC CELLS ISOLATED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS; IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB
    2024-517842-33-01 1 country 2024 n=113
    Recruiting

Phase I (First in Human)

6 trials
  • Curevac AG Commercial
    IMP not specified
    2022-501423-25-00 3 countries 2023 n=54
    Ended
  • Genenta Science S.p.A. Commercial
    IMP not specified
    2023-510299-29-00 1 country 2019 n=27
    Ended
  • Hemerion Therapeutics Commercial
    AMINOLEVULINIC ACID HYDROCHLORIDE
    2025-520563-41-00 1 country 2025 n=6 Orphan
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    SULFUR HEXAFLUORIDE
    2024-516169-35-00 1 country 2023 n=24
    Recruiting
  • Centre Jean Perrin Academic
    GADOLINIUM-CHELATED POLYSILOXANE NANOPARTICLES
    2024-517114-15-00 1 country 2025 n=66
    Ended
  • UZ Brussel Academic
    IMP not specified
    2023-508278-26-01 1 country 2024 n=18
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 3 Phase I (Other), Phase I/II 0
Oslo University Hospital HF Academic 3 Phase II/III, Phase I (Other), Phase II 2
UZ Brussel Academic 2 Phase I (Other), Phase I (First in Human) 1
Universitaet Muenster Academic 2 Phase II, Phase I/II 1
Double Bond Pharmaceutical AB Commercial 1 Phase I 0
Merck Healthcare KGaA Commercial 1 Phase I 1
Global Coalition For Adaptive Research Inc. Commercial 1 Phase II/III 0
Laminar Pharmaceuticals S.A. Commercial 1 Phase II/III 0
Boehringer Ingelheim International GmbH Commercial 1 Phase I (Other) 0
Celgene Corp. Commercial 1 Phase I (Other) 0
Exelixis Inc. Commercial 1 Phase I (Other) 0
Oncopeptides AB Commercial 1 Phase I (Other) 0
Carthera Commercial 1 Phase III 0
Novocure GmbH Commercial 1 Phase III 1
Telix Pharmaceuticals (Innovations) Pty Limited Commercial 1 Phase III 1
Curevac AG Commercial 1 Phase I (First in Human) 0
Genenta Science S.p.A. Commercial 1 Phase I (First in Human) 0
Hemerion Therapeutics Commercial 1 Phase I (First in Human) 0
Debiopharm International S.A. Commercial 1 Phase I/II 1
TME Pharma AG Commercial 1 Phase I/II 1
New trials by year
2019
5
2020
1
2021
1
2022
7
2023
8
2024
7
2025
8
2026
2
← All indication landscapes